PIK3CA and neoplasm: The significantly enhanced anti-tumor activity observed across a diverse set of RTK-driven tumor models treated with combinations that vertically inhibit the PI3K/AKT/eIF4F pathway suggest that combination of zotatifin with PI3K or AKT inhibitors can result in enhanced activity for these targeted agents.